Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force | Cancer Screening, Prevention, Control | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.170.64.36. Please contact the publisher to request reinstatement.
1.
Thomas  VD, Aasi  SZ, Wilson  LD, Leffell  DJ. Cancer of the skin. In: DeVita  VT, Lawrence  TS, Rosenberg  SA, DePinho  RA, Weinberg  RA, eds.  DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 8th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2008:1863-1887.
2.
Howlader  N, Noone  AM, Krapcho  M,  et al. SEER Cancer Statistics Review, 1975-2011 [based on November 2013 SEER data submission]. Surveillance, Epidemiology, and End Results Program. April 2014. http://seer.cancer.gov/archive/csr/1975_2011/. Accessed April 1, 2015.
3.
Siegel  RL, Miller  KD, Jemal  A.  Cancer statistics, 2015.  CA Cancer J Clin. 2015;65(1):5-29.PubMedGoogle ScholarCrossref
4.
US Preventive Services Task Force.  Screening for skin cancer: US Preventive Services Task Force recommendation statement.  Ann Intern Med. 2009;150(3):188-193.PubMedGoogle ScholarCrossref
5.
US Preventive Services Task Force.  Screening for skin cancer: recommendations and rationale.  Am J Prev Med. 2001;20(3)(suppl):44-46.PubMedGoogle ScholarCrossref
6.
Wernli  KJ, Henrikson  NB, Morrison  CC, Nguyen  M, Pocobelli  G, Whitlock  EP.  Screening for Skin Cancer in Adults: An Updated Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 137. Rockville, MD: Agency for Healthcare Research and Quality; 2016. AHRQ publication 14-05210-EF-1.
7.
US Preventive Services Task Force.  US Preventive Services Task Force Procedure Manual. Rockville, MD: Agency for Healthcare Research and Quality; 2008. AHRQ publication 08-05118-EF.
8.
Human development data (1980-2015). United Nations Development Programme. http://hdr.undp.org/en/data. Accessed May 22, 2015.
9.
Byrd  D, Compton  CC, Fritz  AG, Greene  FL, Trotti  A.  AJCC Cancer Staging Manual. Vol 649. New York, NY: Springer; 2010.
10.
Dufault  B, Klar  N.  The quality of modern cross-sectional ecologic studies: a bibliometric review.  Am J Epidemiol. 2011;174(10):1101-1107.PubMedGoogle ScholarCrossref
11.
Tu  JV, Ko  DT.  Ecological studies and cardiovascular outcomes research.  Circulation. 2008;118(24):2588-2593.PubMedGoogle ScholarCrossref
12.
Katalinic  A, Waldmann  A, Weinstock  MA,  et al.  Does skin cancer screening save lives? an observational study comparing trends in melanoma mortality in regions with and without screening.  Cancer. 2012;118(21):5395-5402.PubMedGoogle ScholarCrossref
13.
Waldmann  A, Nolte  S, Geller  AC,  et al.  Frequency of excisions and yields of malignant skin tumors in a population-based screening intervention of 360,288 whole-body examinations.  Arch Dermatol. 2012;148(8):903-910.PubMedGoogle ScholarCrossref
14.
Breitbart  EW, Waldmann  A, Nolte  S,  et al.  Systematic skin cancer screening in Northern Germany.  J Am Acad Dermatol. 2012;66(2):201-211.PubMedGoogle ScholarCrossref
15.
Gambichler  T, Senger  E, Rapp  S, Alamouti  D, Altmeyer  P, Hoffmann  K.  Deep shave excision of macular melanocytic nevi with the razor blade biopsy technique.  Dermatol Surg. 2000;26(7):662-666.PubMedGoogle ScholarCrossref
16.
Aitken  JF, Janda  M, Elwood  M, Youl  PH, Ring  IT, Lowe  JB.  Clinical outcomes from skin screening clinics within a community-based melanoma screening program.  J Am Acad Dermatol. 2006;54(1):105-114.PubMedGoogle ScholarCrossref
17.
Fritschi  L, Dye  SA, Katris  P.  Validity of melanoma diagnosis in a community-based screening program.  Am J Epidemiol. 2006;164(4):385-390.PubMedGoogle ScholarCrossref
18.
Aitken  JF, Elwood  M, Baade  PD, Youl  P, English  D.  Clinical whole-body skin examination reduces the incidence of thick melanomas.  Int J Cancer. 2010;126(2):450-458.PubMedGoogle ScholarCrossref
19.
Marashi-Pour  S, Morrell  S, Cooke-Yarborough  C, Arcorace  M, Baker  D.  Competing risk analysis of mortality from invasive cutaneous melanoma in New South Wales: a population-based study, 1988-2007.  Aust N Z J Public Health. 2012;36(5):441-445.PubMedGoogle ScholarCrossref
20.
Green  AC, Baade  P, Coory  M, Aitken  JF, Smithers  M.  Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia.  J Clin Oncol. 2012;30(13):1462-1467.PubMedGoogle ScholarCrossref
21.
Pollack  LA, Li  J, Berkowitz  Z,  et al.  Melanoma survival in the United States, 1992 to 2005.  J Am Acad Dermatol. 2011;65(5)(suppl 1):S78-S86.PubMedGoogle ScholarCrossref
22.
Zell  JA, Cinar  P, Mobasher  M, Ziogas  A, Meyskens  FL  Jr, Anton-Culver  H.  Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.  J Clin Oncol. 2008;26(1):66-75.PubMedGoogle ScholarCrossref
23.
Reyes-Ortiz  CA, Goodwin  JS, Freeman  JL, Kuo  Y-F.  Socioeconomic status and survival in older patients with melanoma.  J Am Geriatr Soc. 2006;54(11):1758-1764.PubMedGoogle ScholarCrossref
24.
Leiter  U, Buettner  PG, Eigentler  TK, Garbe  C.  Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society.  J Clin Oncol. 2004;22(18):3660-3667.PubMedGoogle ScholarCrossref
25.
Luke  CG, Coventry  BJ, Foster-Smith  EJ, Roder  DM.  A critical analysis of reasons for improved survival from invasive cutaneous melanoma.  Cancer Causes Control. 2003;14(9):871-878.PubMedGoogle ScholarCrossref
26.
Owen  SA, Sanders  LL, Edwards  LJ, Seigler  HF, Tyler  DS, Grichnik  JM.  Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.  Cancer. 2001;91(5):983-991.PubMedGoogle ScholarCrossref
27.
Harris  RP, Helfand  M, Woolf  SH,  et al; Methods Work Group, Third US Preventive Services Task Force.  Current methods of the US Preventive Services Task Force: a review of the process.  Am J Prev Med. 2001;20(3)(suppl):21-35.PubMedGoogle ScholarCrossref
28.
Boniol  M, Autier  P, Gandini  S.  Melanoma mortality following skin cancer screening in Germany.  BMJ Open. 2015;5(9):e008158.PubMedGoogle ScholarCrossref
29.
Stell  VH, Norton  HJ, Smith  KS, Salo  JC, White  RL  Jr.  Method of biopsy and incidence of positive margins in primary melanoma.  Ann Surg Oncol. 2007;14(2):893-898.PubMedGoogle ScholarCrossref
30.
Welch  HG, Woloshin  S, Schwartz  LM.  Skin biopsy rates and incidence of melanoma: population based ecological study.  BMJ. 2005;331(7515):481.PubMedGoogle ScholarCrossref
31.
Welch  HG, Black  WC.  Overdiagnosis in cancer.  J Natl Cancer Inst. 2010;102(9):605-613.PubMedGoogle ScholarCrossref
32.
Rogers  HW, Weinstock  MA, Harris  AR,  et al.  Incidence estimate of nonmelanoma skin cancer in the United States, 2006.  Arch Dermatol. 2010;146(3):283-287.PubMedGoogle ScholarCrossref
33.
Linos  E, Schroeder  SA, Chren  MM.  Potential overdiagnosis of basal cell carcinoma in older patients with limited life expectancy.  JAMA. 2014;312(10):997-998.PubMedGoogle ScholarCrossref
34.
Youl  PH, Baade  PD, Janda  M, Del Mar  CB, Whiteman  DC, Aitken  JF.  Diagnosing skin cancer in primary care: how do mainstream general practitioners compare with primary care skin cancer clinic doctors?  Med J Aust. 2007;187(4):215-220.PubMedGoogle Scholar
35.
Wise  E, Singh  D, Moore  M,  et al.  Rates of skin cancer screening and prevention counseling by US medical residents.  Arch Dermatol. 2009;145(10):1131-1136.PubMedGoogle ScholarCrossref
36.
Fears  TR, Guerry  D  IV, Pfeiffer  RM,  et al.  Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.  J Clin Oncol. 2006;24(22):3590-3596.PubMedGoogle ScholarCrossref
37.
Cho  E, Rosner  BA, Feskanich  D, Colditz  GA.  Risk factors and individual probabilities of melanoma for whites.  J Clin Oncol. 2005;23(12):2669-2675.PubMedGoogle ScholarCrossref
38.
Williams  LH, Shors  AR, Barlow  WE, Solomon  C, White  E.  Identifying persons at highest risk of melanoma using self-assessed risk factors.  J Clin Exp Dermatol Res. 2011;2(6):1000129.PubMedGoogle Scholar
39.
Davies  JR, Chang  YM, Bishop  DT,  et al.  Development and validation of a melanoma risk score based on pooled data from 16 case-control studies.  Cancer Epidemiol Biomarkers Prev. 2015;24(5):817-824.PubMedGoogle ScholarCrossref
40.
GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for Research on Cancer. http://globocan.iarc.fr/Pages/Map.aspx. Accessed May 22, 2015.
41.
Preventing skin cancer: child care center-based interventions. Guide to Community Preventive Services. http://www.thecommunityguide.org/cancer/skin/education-policy/childcarecenters.html. Accessed December 1, 2015.
42.
Preventing skin cancer: interventions in outdoor occupational settings. Guide to Community Preventive Services. http://www.thecommunityguide.org/cancer/skin/education-policy/outdooroccupations.html. Accessed December 1, 2015.
43.
Preventing skin cancer: interventions in outdoor recreational and tourism settings. Guide to Community Preventive Services. http://www.thecommunityguide.org/cancer/skin/education-policy/outdoorrecreation.html. Accessed December 1, 2015.
44.
Preventing skin cancer: primary and middle school-based interventions. Guide to Community Preventive Services. http://www.thecommunityguide.org/cancer/skin/education-policy/primaryandmiddleschools.html. Accessed December 1, 2015.
45.
Preventing skin cancer: multicomponent community-wide interventions. Guide to Community Preventive Services. http://www.thecommunityguide.org/cancer/skin/community-wide/multicomponent.html. Accessed December 1, 2015.
46.
Moyer  VA; US Preventive Services Task Force.  Behavioral counseling to prevent skin cancer: US Preventive Services Task Force recommendation statement.  Ann Intern Med. 2012;157(1):59-65.PubMedGoogle ScholarCrossref
US Preventive Services Task Force
Evidence Report
July 26, 2016

Screening for Skin Cancer in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force

Author Affiliations
  • 1Group Health Research Institute, Kaiser Permanente Research Affiliates Evidence-based Practice Center, Seattle, Washington
JAMA. 2016;316(4):436-447. doi:10.1001/jama.2016.5415
Abstract

Importance  Skin cancer, primarily melanoma, is a leading cause of morbidity and mortality in the United States.

Objective  To provide an updated systematic review for the US Preventive Services Task Force regarding clinical skin cancer screening among adults.

Data Sources  MEDLINE, PubMed, and the Cochrane Central Register of Controlled Trials were searched for relevant studies published from January 1, 1995, through June 1, 2015, with surveillance through February 16, 2016.

Study Selection  English-language studies conducted in asymptomatic populations 15 years and older at general risk for skin cancer.

Data Extraction and Synthesis  Relevant data were abstracted, and study quality was rated.

Main Outcomes and Measures  Melanoma incidence and mortality, harms from cancer screening, diagnostic accuracy, and stage distribution.

Results  No randomized clinical trials were identified. There was limited evidence on the association between skin cancer screening and mortality. A German ecologic study (n = 360 288) found a decrease of 0.8 per 100 000 melanoma deaths in a region with population-based skin cancer screening compared with no change or slight increases in comparison regions. The number of excisions needed to detect 1 skin cancer from clinical visual skin examinations varied by age and sex; for example, 22 for women 65 years or older compared with 41 for women aged 20 to 34 years. In 2 studies of performing visual skin examination, sensitivity to detect melanoma was 40.2% and specificity was 86.1% when conducted by primary care physicians (n = 16 383). Sensitivity was 49.0% and specificity was 97.6% when skin examinations were performed by dermatologists (n = 7436). In a case-control study of melanoma (n = 7586), cases diagnosed with thicker lesions (>0.75 mm) had an odds ratio of 0.86 (95% CI, 0.75-0.98) for receipt of a physician skin examination in the prior 3 years compared with controls. Eight cohort studies (n = 236 485) demonstrated a statistically significant relationship between the degree of disease involvement at diagnosis and melanoma mortality, regardless of the characterization of the stage or lesion thickness. Tumor thickness greater than 4.0 mm was associated with increased melanoma mortality compared with thinner lesions, and late stage at diagnosis was associated with increased all-cause mortality.

Conclusions and Relevance  Only limited evidence was identified for skin cancer screening, particularly regarding potential benefit of skin cancer screening on melanoma mortality. Future research on skin cancer screening should focus on evaluating the effectiveness of targeted screening in those considered to be at higher risk for skin cancer.

×